Genetics and Pathophysiology of Cystic Fibrosis

Kendig's Disorders of the Respiratory Tract in Children

Volumn , Issue , 2006, Pages 848-860

  Cutting, Garry R ^a   Zeitlin, Pamela L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649655688     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-3695-5.50062-6     Document Type: Chapter

References (160)

1. Andersen DH, Hodges RG Celiac syndrome. Am J Dis Child 1946, 72:62-80.
2. Knowlton RG, Cohen-Haguenauer O, Van Cong N, et al. A polymorphic DNA marker linked to cystic fibrosis is located on chromosome 7. Nature 1985, 318:380-382.
3. Tsui LC, Buchwald M, Barker D, et al. Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker. Science 1985, 239:1054-1057.
4. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene. Chromosome walking and jumping. Science 1989, 245:1059-1065.
5. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene. Cloning and characterization of complementary DNA. Science 1989, 245:1066-1073.
6. Ellsworth RE, Jamison DC, Touchman JW, et al. Comparative genomic sequence analysis of the human and mouse cystic fibrosis transmembrane conductance regulator genes. proc Natl Acad Sci USA 2000, 97:1172-1177.
7. Thomas JW, Touchman JW, Blakesley RW, et al. Comparative analyses of multi-species sequences from targeted genomic regions. Nature 2003, 424:788-793.
8. Chou J-L, Rozmahel R, Tsui LC Characterization of the promoter region of the cystic fibrosis transmembrane conductance regulator gene. J Biol Chem 1991, 266:24471-24476.
9. Koh J, Sferra TJ, Collins FS Characterization of the cystic fibrosis transmembrane conductance regulator promoter region. J Biol Chem 1993, 268:15912-15921.
10. Yoshimura K, Nakamura H, Trapnell BC, et al. The cystic fibrosis gene has a "housekeeping"-type promoter and is expressed at low levels in cells of epithelial origin. J Biol Chem 1991, 266:9140-9144.
11. Engelhardt JF, Yankaskas JR, Ernst SA, et al. Submucosal glands are the predominant site of CFTR expression in the human bronchus. Nat Genet 1992, 2:240-247.
12. Tizzano EF, Chitayat D, Buchwald M Cell-specific localization of CFTR mRNA shows developmentally regulated expression in human fetal tissues. Hum Mol Genet 1993, 2:219-224.
13. Trezise AEO, Chambers JA, Wardle CJ, et al. Expression of the cystic fibrosis gene in human foetal tissues. Hum Mol Genet 1993, 2(3):213-218.
14. Matthews RP, McKnight GS Characterization of the cAMP response element of the cystic fibrosis transmembrane conductance regulator gene promoter. J Biol Chem 1996, 271:31869-31877.
15. Moulin DS, Manson AL, Nuthall HN, et al. In vivo analysis of DNase I hypersensitive sites in the human CFTR gene. Mol Med 1999, 5:211-223.
16. Nuthall HN, Vassaux G, Huxley C, Harris A Analysis of a DNase I hypersensitive site located -20.9 kb upstream of the CFTR gene. Eur J Biochem 1999, 266:431-443.
17. Smith DJ, Nuthall HN, Majetti ME, Harris A Multiple potential intragenic regulatory elements in the CFTR gene. Genomics 2000, 64:90-96.
18. Ulatowski LM, Whitmore KL, Romigh T, et al. Strain-specific variants of the mouse Cftr promoter region reveal transcriptional regulatory elements. Hum Mol Genet 2004, 13:1933-1941.
19. Cutting GR Splicing of the CFTR gene. Current Topics in Cystic Fibrosis 1994, II:55-74. Wiley & Sons, Chichester. J.A. Dodge, D.J.H. Brock, J.H. Widdicombe (Eds.).
20. Hull J, Shackleton S, Harris A Analysis of mutations and alternative splicing patterns in the CFTR gene using mRNA derived from nasal epithelial cells. Hum Mol Genet 1994, 3:1141-1146.
21. Horowitz B, Tsung SS, Hart P, et al. Alternative splicing of CFTR Cl- channels in the heart. Am J Physiol 1993, 264(6):H2214-H2220. pt. 2.
22. Hart P, Warth JD, Levesque PC, et al. Cystic fibrosis gene encodes a cAMP-dependent chloride channel in heart. proc Natl Acad Sci USA 1996, 93:6343-6348.
23. Xie J, Drumm ML, Zhao J, et al. Human epithelial cystic fibrosis transmembrane conductance regulator without exon 5 maintains partial chloride channel function in intracellular membranes. Biophys J 1996, 71:3148-3156.
24. Morelos MM, Carroll TP, Morita T, et al. Both the wild type and a functional isoform of CFTR are expressed in kidney. Am J Physiol 1996, 270:F1038-F1048.
25. Chu C-S, Trapnell BC, Murtagh JJ, et al. Variable deletion of exon 9 coding sequences in cystic fibrosis transmembrane conductance regulator gene mRNA transcripts in normal bronchial epithelium. EMBO J 1991, 10:1355-1363.
26. Strong TV, Wilkinson DJ, Mansoura MK, et al. Expression of an abundantly alternatively spliced form of the cystic fibrosis transmembrane conductance regulator (CFTR) gene is not associated with a cAMP-activated chloride conductance. Hum Mol Genet 1993, 2:225-230.
27. Chu C-S, Trapnell BC, Curristin S, et al. Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat Genet 1993, 3:151-156.
28. Chu C-S, Trapnell BC, Curristin SM, et al. Extensive post-translational deletion of the coding sequences for part of nucleotide-binding fold 1 in respiratory epithelial mRNA transcripts of the cystic fibrosis transmembrane conductance regulator gene is not associated with the clinical manifestations of cystic fibrosis. J Clin Invest 1992, 90:785-790.
29. Niksic M, Romano M, Buratti E, et al. Functional analysis of cis-acting elements regulating the alternative splicing of human CFTR exon 9. Hum Mol Genet 1999, 8:2339-2349.
30. Pagani F, Buratti E, Stuani C, et al. Splicing factors induce cystic fibrosis transmembrane regulator exon 9 skipping through a nonevolutionarily conserved intronic element. J Biol Chem 2000, 275:21041-21047.
31. Hefferon TW, Broackes-Carter FC, Harris A, Cutting GR Atypical 5' splice sites cause CFTR exon 9 to be vulnerable to skipping. Am J Hum Genet 2002, 71:294-303.
32. Mak V, Jarvi K, Zielenski J, et al. Higher proportion of intact exon 9 CFTR MRNA in nasal epithelium compared with vas deferens. Hum Mol Genet 1997, 6:2099-2107.
33. Teng H, Jorissen M, Poppel H, et al. Increased proportion of exon 9 alternatively spliced CFTR transcripts in vas deferens compared with nasal epithelial cells. Hum Mol Genet 1997, 6:85-90.
34. Cuppens H, Lin W, Jaspers M, et al. Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (TG)m locus explains the partial penetrance of the 5T polymorphism as a disease mutation. J Clin Invest 1998, 101:487-496.
35. Buratti E, Dork T, Zuccato E, et al. Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J 2001, 20:1774-1784.
36. Hefferon TW, Groman JD, Yurk CE, Cutting GR A variable dinucleotide repeat in the CFTR gene contributes to phenotype diversity by forming RNA secondary structures that alter splicing. proc Natl Acad Sci USA 2004, 101:3504-3509.
37. Groman JD, Hefferon TW, Casals T, et al. Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. Am J Hum Genet 2004, 74:176-179.
38. Will K, Stuhrmann M, Dean M, Schmidtke J Alternative splicing in the first nucleotide binding fold of CFTR. Hum Mol Genet 1993, 2:231-235.
39. Melo CA, Serra C, Stoyanova V, et al. Alternative splicing of a previously unidentified CFTR exon introduces an in-frame stop codon 5' of the R region. FEBS Lett 1993, 329(1,2):159-162.
40. Delaney SJ, Rich DP, Thomson SA, et al. Cystic fibrosis transmembrane conductance regulator splice variants are not conserved and fail to produce chloride channels. Nat Genet 1993, 4:426-430.
41. Slomski R, Schloesser M, Berg LP, et al. Omission of exon 12 in cystic fibrosis transmembrane conductance regulator (CFTR) gene transcripts. Hum Genet 1992, 89:615-619.
42. Yoshimura K, Chu CS, Crystal RG Alternative splicing of intron 23 of the human cystic fibrosis transmembrane conductance regulator gene resulting in a novel exon and transcript coding for a shortened intracytoplasmic C terminus. J Biol Chem 1993, 268:686-690.
43. Romey MC, Guittard C, Chazalette JP, et al. Complex allele [-102T> A + S549R(T>G)] is associated with milder forms of cystic fibrosis than allele S549R(T>G) alone. Hum Genet 1999, 105:145-150.
44. Wang X, Moylan B, Leopold DA, et al. Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. JAMA 2000, 284:1814-1819.
45. Aznarez I, Chan EM, Zielenski J, et al. Characterization of disease-associated mutations affecting an exonic splicing enhancer and two cryptic splice sites in exon 13 of the cystic fibrosis transmembrane conductance regulator gene. Hum Mol Genet 2003, 12:2031-2040.
46. Steiner B, Truninger K, Sanz J, et al. The role of common single-nucleotide polymorphisms on exon 9 and exon 12 skipping in nonmutated CFTR alleles. Hum Mutat 2004, 24:120-129.
47. Bobadilla JL, Macek M, Fine JP, Farrell PM Cystic fibrosis. A worldwide analysis of CFTR mutations-correlation with incidence data and application to screening. Hum Mutat 2002, 19:575-606.
48. WHO/ECFTN/ICF(M)A/EC. F. S.: The molecular genetic epidemiology of cystic fibrosis. Report of a joint meeting of WHO/ECFTN/ICF(M)A/ECFS, Genoa, Italy, 19 June 2002. 6-19-2002. WHO.
49. Cutting GR, Curristin SM, Nash E, et al. Analysis of four diverse population groups indicates that a subset of cystic fibrosis mutations occur in common among Caucasians. Am J Hum Genet 1992, 50:1185-1194.
50. Macek M, Macoková A, Hamosh A, et al. Identification of common CF mutations in African-Americans with cystic fibrosis increases the detection rate to 75%. Am J Hum Genet 1997, 60:1122-1127.
51. Carles S, Desgeorges M, Goldman A, et al. First report of CFTR mutations in black cystic fibrosis patients of southern African origin. J Med Genet 1996, 33:802-804.
52. Macek M, Hamosh A, Kiesewetter S, et al. Identification of a novel nonsense mutation (L88X) in exon 3 of the CFTR gene on a native Korean cystic fibrosis chromosome. Hum Mutat 1992, 1:501-502.
53. Macek M, Mercier B, Macková A, et al. Sensitivity of the denaturing gradient gel electrophoresis technique in detection of known mutations and novel Asian mutations in the CFTR gene. Hum Mutat 1997, 9:136-147.
54. Estivill X, Bancells C, Ramos C Geographic distribution and regional origin of 272 cystic fibrosis mutations in European populations. The Biomed CF Mutation Analysis Consortium. Hum Mutat 1997, 10:135-154.
55. Zielenski J, Fujiwara TM, Markiewicz D, et al. Identification of the M1101K mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and complete detection of cystic fibrosis mutations in the Hutterite population. Am J Med Genet 1993, 52:609-615.
56. Grody WW, Cutting GR, Klinger KW, et al. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med 2001, 3:149-154.
57. Cheadle JP, Goodchild MC, Meredith AL Direct sequencing of the complete CFTR gene. The molecular characterisation of 99.5% of CF chromosomes in Wales. Hum Mol Genet 1993, 2:1551-1556.
58. Girodon-Boulandet E, Cazeneuve C, Goossens M Screening practices for mutations in the CFTR gene ABCC7. Hum Mutat 2000, 15:135-149.
59. Riordan JR Assembly of functional CFTR chloride channels. Annu Rev Physiol 2005, 67:701-718.
60. Nilius B, Droogmans G Amazing chloride channels. An overview. Acta Physiol Scand 2003, 177:119-147.
61. Drumm ML, Wilkinson DJ, Smit LS, et al. Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes. Science 1991, 254:1797-1799.
62. Hwang TC, Lu L, Zeitlin PL, et al. Cl- channels in CF. Lack of activation by protein kinase C and cAMP-dependent protein kinase. Science 1989, 244:1351-1353.
63. Lewis HA, Zhao X, Wang C, et al. Impact of the ΔF508 mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure. J Biol Chem 2005, 280:1346-1353.
64. Horster M Embryonic epithelial membrane transporters. Am J Physiol Renal Physiol 2000, 279:F982-F996.
65. Barker PM, Boucher RC, Yankaskas JR Bioelectric properties of cultured monolayers from epithelium of distal human fetal lung. Am J Physiol 1995, 268:L270-L277.
66. + transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation. J Clin Invest 1986, 78:1245-1252.
67. Gabriel SE, Clarke LL, Boucher RC, Stutts MJ CFTR and outward rectifying chloride channels are distinct proteins with a regulatory relationship. Nature 1993, 363:263-268.
68. Welsh MJ, Smith AE Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993, 73:1251-1254.
69. Frischmeyer PA, Dietz HC Nonsense-mediated mRNA decay in health and disease. Hum Mol Genet 1999, 8:1893-1900.
70. Hamosh A, Trapnell BC, Zeitlin PL, et al. Severe deficiency of CFTR mRNA carrying nonsense mutations R553X and W1316X in respiratory epithelial cells of patients with cystic fibrosis. J Clin Invest 1991, 88:1880-1885.
71. Rolfini R, Cabrini G Nonsense mutation R1162X of the cystic fibrosis transmembrane conductance regulator gene does not reduce messenger RNA expression in nasal epithelial tissue. J Clin Invest 1993, 92:2683-2687.
72. Will K, Dörk T, Stuhrmann M, et al. Transcript analysis of CFTR nonsense mutations in lymphocytes and nasal epithelial cells from cystic fibrosis patients. Hum Mutat 1995, 5:210-220.
73. Dietz HC, Valle D, Francomano CA, et al. The skipping of constitutive exons in vivo induced by nonsense mutations. Science 1993, 259:680-683.
74. Hull J, Shackleton S, Harris A The stop mutation R553X in the CFTR gene results in exon skipping. Genomics 1994, 19:362-364.
75. Zielenski J, Bozon D, Markiewicz D, et al. Analysis of CFTR transcripts in nasal epithelial cells and lymphoblasts of a cystic fibrosis patient with 621 + 1G → T and 711 + 1G → T mutations. Hum Mol Genet 1993, 2:683-687.
76. Cheng SH, Gregory RJ, Marshall J, et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 1990, 63:827-834.
77. Kartner N, Augustinas O, Jensen TJ, et al. Mislocalization of ΔF508 CFTR in cystic fibrosis sweat gland. Nat Genet 1992, 1:321-327.
78. Jensen TJ, Loo MA, Pind S, et al. Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 1995, 83:129-135.
79. Denning GM, Anderson MP, Amara JF, et al. processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 1992, 358:761-764.
80. Lukacs GL, Chang X-B, Bear C, et al. The ΔF508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. J Biol Chem 1993, 268(29):21592-21598.
81. - channel activity compensates for defective processing in a mild form of the disease. EMBO J 1995, 14:2417-2423.
82. Sheppard DN, Ostedgaard LS, Winter MC, Welsh MJ Mechanism of dysfunction of two nucleotide binding domain mutations in cystic fibrosis transmembrane conductance regulator that are associated with pancreatic sufficiency. EMBO J 1995, 14:876-883.
83. Anderson MP, Welsh MJ Regulation by ATP and ADP of CFTR chloride channels that contain mutant nucleotide-binding domains. Science 1992, 257:1701-1704.
84. Logan J, Hiestand D, Daram P, et al. Cystic fibrosis transmembrane conductance regulator mutations that disrupt nucleotide binding. J Clin Invest 1994, 94:228-236.
85. Strong TV, Smit LS, Turpin SV, et al. Cystic fibrosis gene mutation in two sisters with mild disease and normal sweat electrolyte levels. N Engl J Med 1991, 325:1630-1634.
86. - channels with altered pore properties. Nature 1993, 362:160-164.
87. Tabcharani JA, Rommens JM, Hou Y-X, et al. Multi-ion pore behavior in the CFTR chloride channel. Nature 1993, 366(4):79-82.
88. Highsmith WE, Burch LH, Zhou Z, et al. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 1994, 331:974-980.
89. Schwiebert EM, Benos DJ, Egan ME, et al. CFTR is a conductance regulator as well as a chloride channel. Physiol Rev 1999, 79:S145-S166.
90. Fulmer SB, Schwiebert EM, Morales MM, et al. Two cystic fibrosis transmembrane conductance regulator mutations have different effects on both pulmonary phenotype and regulation of outwardly rectified chloride currents. proc Natl Acad Sci USA 1995, 92:6832-6836.
91. Ismailov II, Awayda MS, Jovov B, et al. Regulation of epithelial sodium channels by the cystic fibrosis transmembrane conductance regulator. J Biol Chem 1996, 271:4725-4732.
92. Moyer BD, Denton J, Karlson KH, et al. A PDZ-interacting domain in CFTR is an apical membrane polarization signal. J Clin Invest 1999, 104:1353-1361.
93. Fu J, Ji HL, Naren AP, Kirk KL A cluster of negative charges at the amino terminal tail of CFTR regulates ATP-dependent channel gating. J Physiol 2001, 536:459-470.
94. Cystic Fibrosis Genotype/Phenotype Consortium Correlation between genotype and phenotype in cystic fibrosis. N Engl J Med 1993, 329:1308-1313.
95. Knowles MR, Durie PR What is cystic fibrosis?. N Engl J Med 2002, 347:439-442.
96. Kristidis P, Bozon D, Corey M, et al. Genetic determination of exocrine pancreatic function in cystic fibrosis. Am J Hum Genet 1992, 50:1178-1184.
97. Wilschanski M, Zielenski J, Markiewicz D, et al. Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations. J Pediatr 1995, 127:705-710.
98. Gan K-H, Veeze HJ, Van den Ouweland, et al. A cystic fibrosis mutation associated with mild lung disease. N Engl J Med 1995, 333:95-99.
99. De Braekeleer M, Allard C, Leblanc J-P, et al. Genotype-phenotype correlation in cystic fibrosis patients compound heterozygous for the A455E mutation. Hum Genet 1997, 101:208-211.
100. Koch C, Cuppens H, Rainisio M, et al. European Epidemiologic Registry of Cystic Fibrosis (ERCF). Comparison of major disease manifestations between patients with different classes of mutations. Pediatr Pulmonol 2001, 31:1-12.
101. Ferec C, Verlingue C, Guillermit H, et al. Genotype analysis of adult cystic fibrosis patients. Hum Mol Genet 1993, 2:1557-1560.
102. Brancolini V, Cremonesi L, Belloni E, et al. Search for mutations in pancreatic sufficient cystic fibrosis Italian patients. Detection of 90% of molecular defects and identification of three novel mutations. Hum Genet 1995, 96:312-318.
103. Lebecque P, Leal T, De Boeck C, et al. Mutations of the cystic fibrosis gene and intermediate sweat chloride levels in children. Am J Respir Crit Care Med 2002, 165:757-761.
104. Feldmann D, Coudere R, Audrezet MP, et al. CFTR genotypes in patients with normal or borderline sweat chloride levels. Hum Mutat 2003, 22:340.
105. McKone EF, Emerson SS, Edwards KL, Aitken ML Effect of genotype on phenotype and mortality in cystic fibrosis. A retrospective cohort study. Lancet 2003, 361:1671-1676.
106. Hamosh A, King TM, Rosenstein BJ, et al. Cystic fibrosis patients bearing the common missense mutation Gly→Asp at codon 551 and the ΔF508 are indistinguishable from ΔF508 homozygotes except for decreased risk of meconium ileus. Am J Hum Genet 1992, 51:245-250.
107. Goris ML, Zhu HJ, Blankenberg F, et al. An automated approach to quantitative air trapping measurements in mild cystic fibrosis. Chest 2003, 123:1655-1663.
108. Tandon R, Derkay C Contemporary management of rhinosinusitis and cystic fibrosis. Curr Opin Otolaryngol Head Neck Surg 2003, 11:41-44.
109. Konstan MW, Hilliard KA, Norvell TM, Berger M Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994, 150:448-454.
110. Khan TZ, Wagner JS, Bost T, et al. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995, 151:1075-1082.
111. Armstrong DS, Grimwood K, Carlin JB, et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997, 156:1197-1204.
112. Doring G, Hoiby N Early intervention and prevention of lung disease in cystic fibrosis. A European consensus. J Cyst Fibros 2004, 3:67-91.
113. Saiman L, Siegel J Infection control in cystic fibrosis. Clin Microbiol Rev 2004, 17:57-71.
114. Kaplan E, Schwachman H, Perlmutter AD, et al. Reproductive failure in males with cystic fibrosis. N Engl J Med 1968, 279:65-69.
115. Wilschanski M, Corey M, Durie P, et al. Diversity of reproductive tract abnormalities in men with cystic fibrosis. JAMA 1996, 276:607-608.
116. McKusick VA: Online Mendelian Inheritance in Man [abstract]. Johns Hopkins Institute for Genetic Medicine, Johns Hopkins University. Available at. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM.
117. Anguiano A, Oates RD, Amos JA, et al. Congenital bilateral absence of the vas deferens-a primarily genital form of cystic fibrosis. JAMA 1992, 267:1794-1797.
118. Claustres M, Guittard C, Bozon D, et al. Spectrum of CFTR mutations in cystic fibrosis and in congenital absence of the vas deferens in France. Hum Mutat 2000, 16:143-156.
119. Chillón M, Casals T, Mercier B, et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med 1995, 332:1475-1480.
120. Kiesewetter S, Macek M, Davis C, et al. A mutation in the cystic fibrosis transmembrane conductance regulator gene produces different pheno-types depending on chromosomal background. Nat Genet 1993, 5:274-278.
121. Cohn JA, Friedman KJ, Noone PG, et al. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med 1998, 339:653-658.
122. Witt DR, Hallam P, Wi S, et al. Cystic fibrosis heterozygote screening in 5,161 pregnant women. Am J Hum Genet 1996, 58:823-835.
123. Welsh MJ, Ramsey BW, Accurso FJ, Cutting GR Cystic fibrosis. The Metabolic and Molecular Bases of Inherited Disease 2001, 5121-5188. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, D. Valle, W.S. Sly (Eds.).
124. Bank S, Marks IN, Novis B Sweat electrolytes in chronic pancreatitis. Am J Dig Dis 1978, 23:178-181.
125. Sharer NS, Schwarz M, Malone G, et al. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med 1998, 339:645-652.
126. Noone PG, Zhou Z, Silverman LM, et al. Cystic fibrosis gene mutations and pancreatitis risk. Relation to epithelial ion transport and trypsin inhibitor gene mutations. Gastroenterology 2001, 121:1310-1319.
127. Audrezet MP, Chen JM, Le Marechal C, et al. Determination of the relative contribution of three genes-the cystic fibrosis transmembrane conductance regulator gene, the cationic trypsinogen gene, and the pancreatic secretory trypsin inhibitor gene-to the etiology of idiopathic chronic pancreatitis. Eur J Hum Genet 2002, 10:100-106.
128. Choudari CP, Imperiale TF, Sherman S, et al. Risk of pancreatitis with mutation of the cystic fibrosis gene. Am J Gastroenterol 2004, 99:1358-1363.
129. Gaia E, Salacone P, Gallo M, et al. Germline mutations in CFTR and PSTI genes in chronic pancreatitis patients. Dig Dis Sci 2002, 47:2416-2421.
130. Malats N, Casals T, Porta M, et al. Cystic fibrosis transmembrane regulator (CFTR) ΔF508 mutation and 5T allele in patients with chronic pancreatitis and exocrine pancreatic cancer. Gut 2001, 48:70-74.
131. Perri F, Piepoli A, Stanziale P, et al. Mutation analysis of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, the cationic trypsinogen (PRSS1) gene, and the serine protease inhibitor, Kazal type 1 (SPINK1) gene in patients with alcoholic chronic pancreatitis. Eur J Hum Genet 2003, 11:687-692.
132. Pradal U, Castellani C, Delmarco A, Mastella G Nasal potential difference in congenital bilateral absence of the vas deferens. Am J Respir Crit Care Med 1998, 158:896-901.
133. Castellani C, Bonizzato A, Pradal U, et al. Evidence of mild respiratory disease in men with congenital absence of the vas deferens. Respir Med 1999, 93:869-875.
134. Raman V, Clary R, Siegrist KL, et al. Increased prevalence of mutations in the cystic fibrosis transmembrane conductance regulator in children with chronic rhinosinusitis. Pediatrics 2002, 109:E13.
135. Coste A, Girodon E, Louis S, et al. Atypical sinusitis in adults must lead to looking for cystic fibrosis and primary ciliary dyskinesia. Laryngoscope 2004, 114:839-843.
136. Hytonen M, Patjas M, Vento SI, et al. Cystic fibrosis gene mutations ΔF508 and 394delTT in patients with chronic sinusitis in Finland. Acta Otolaryngol 2001, 121:945-947.
137. Wang XJ, Kim J, McWilliams R, Cutting GR Increased prevalence of chronic rhinosinusitis in carriers of a cystic fibrosis mutation. Arch Otolaryngol Head Neck Surg 2005, 131:237-240.
138. Cheng SH, Fang SL, Zabner J, et al. Functional activation of the cystic fibrosis trafficking mutant delta F508-CFTR by overexpression. Am J Physiol 1995, 268:L615-L624.
139. Loo MA, Jensen TJ, Cui L, et al. Perturbation of Hsp90 interaction with nascent CFTR prevents its maturation and accelerates its degradation by the proteasome. EMBO J 1998, 17:6879-6887.
140. Ward CL, Omura S, Kopito RR Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 1995, 83:121-127.
141. Ostedgaard LS, Zeiher B, Welsh MJ processing of CFTR bearing the P574H mutation differs from wild-type and ΔF508-CFTR. J Cell Sci 1999, 112:2091-2098.
142. Choo-Kang LR, Zeitlin PL Type I, II, III, IV, and V cystic fibrosis transmembrane conductance regulator defects and opportunities for therapy. Curr Opin Pulm Med 2000, 6:521-529.
143. Li C, Ramjeesingh M, Reyes E, et al. The cystic fibrosis mutation (ΔF508) does not influence the chloride channel activity of CFTR. Nat Genet 1993, 3:311-316.
144. - channel is functional when retained in endoplasmic reticulum of mammalian cells. J Biol Chem 1995, 270:12347-12350.
145. Rubenstein RC, Zeitlin PL A pilot clinical trial of sodium 4-phenylbutyrate (Buphenyl) in ΔF508-homozygous cystic fibrosis patients. Evidence of restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 1998, 157:484-490.
146. Zeitlin PL, Diener-West M, Rubenstein RC, et al. Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther 2002, 6:119-126.
147. Egan ME, Pearson M, Weiner SA, et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 2004, 304:600-602.
148. Clancy JP, Bebok Z, Jones J, et al. A controlled trial of gentamicin to suppress premature stop codons in CF patients [abstract]. Pediatr Pulmonol 1999, 239-240.
149. Wilschanski M, Famini C, Blau H, et al. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med 2000, 161:860-865.
150. Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003, 349:1433-1441.
151. Fischer H, Illek B Effects of genistein on disease-causing mutant CFTRs [abstract]. Pediatr Pulmonol 1998, S17:239.
152. Gondor M, Nixon PA, Devor DC, et al. Genistein stimulates chloride secretion in normal volunteers and CF patients with a G551D mutation [abstract]. Pediatr Pulmonol 1998, S17:253.
153. Hwang TC, Wang F, Yang IC, Reenstra WW Genistein potentiates wild-type and ΔF508-CFTR channel activity. Am J Physiol 1997, 273:C988-C998.
154. Illek B, Fischer H, Santos GF, et al. cAMP-independent activation of CFTR Cl channels by the tyrosine kinase inhibitor genistein. Am J Physiol 1995, 268:C886-C893.
155. Mickle JE, Cutting GR Clinical implications of cystic fibrosis transmembrane conductance regulator mutations. Clin Chest Med 1998, 19:443-458. v.
156. Haardt M, Benharouga M, Lechardeur D, et al. C-terminal truncations destabilize the cystic fibrosis transmembrane conductance regulator without impairing its biogenesis. A novel class of mutation. J Biol Chem 1999, 274:21873-21877.
157. Aitken ML, Moss RB, Waltz DA, et al. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum Gene Ther 2001, 12:1907-1916.
158. Flotte TR, Zeitlin PL, Reynolds TC, et al. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients. A two-part clinical study. Hum Gene Ther 2003, 14:1079-1088.
159. Moss RB, Rodman D, Spencer LT, et al. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis. A multicenter, double-blind, placebo-controlled trial. Chest 2004, 125:509-521.
160. Konstan MW, Davis PB, Wagener JS, et al. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum Gene Ther 2004, 15:1255-1269.